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Invasive pulmonary aspergillosis (IPA) is a rare pathology with increasing incidence mainly in critical care settings and recently
in immunocompetent patients. The mortality of the disease is very high, regardless of an early diagnosis and aggressive treatment.
Here, we report a case of a 56 yr old previously healthy woman who was found unconscious at home and admitted to the emergency
room with mild respiratory insufficiency. In the first 24 hours she developed an acute respiratory failure with new radiographic
infiltrates requiring Intensive CareUnit admission. A severe obstructive patternwith impossibility of ventilation because of bilateral
atelectasis was observed, requiring emergent venovenous extracorporeal membrane oxygenator device insertion. Bronchoscopy
revealed occlusion of main bronchi, demonstrating by biopsy an invasive infection by Aspergillus fumigatus and A. flavus. Despite
an aggressive treatment and vital support the patient had a fatal outcome.The forensic study confirms the diagnosis of IPA but also
revealed the presence of disseminated aspergillosis.
1. Case Presentation
A 56 yr old healthy woman was found at home in coma
and with signs of long-standing immobilization such as
pressure sores and dehydration. She had a history of 14-
pack-year tobacco smoking and dyslipidemia treated with
simvastatin 40mg a day. There was no history of chronic
pulmonary disease or other chronic diseases. Three days
before admission she fell suffering mild head injury. The
following day she was asymptomatic. After two days she
was found in coma and delivered to the emergency room
of our hospital. At hospital admission she had mild res-





bronchospasm, and mild depressed level of consciousness.
Chest radiography was normal (Figure 1(a)(A)). Biochemi-
cal analysis at admission showed acute kidney injury with
urea of 41mmol/L (3.3–8mmol/L), creatinine 120 𝜇mol/L
(0–85𝜇mol/L), and creatine phosphokinase of 15mckat/L
(0.05–2.3). The complete blood count showed hemoglobin of
16.6 g/L and 11,800 leucocytes, D-dimer of 680mcg/L (<200),
and normal clothing times. Brain computed tomography
(CT) scanwas performed and reported as normal and lumbar
puncture revealed a normal cerebrospinal fluid. Thoracic CT
scan ruled out pulmonary thromboembolism but a small
lingula consolidation was observed (see Figure 1(a)(B)).
Initialmanagement included fluid reanimationwith crys-
talloids, bronchodilators, and empiric antibiotics (amoxi-
cillin/clavulanic acid) as suspicion of aspiration pneumonia.
However, 24 hours later she developed severe mixed acute





100mmHg) and respiratory acidosis with pCO
2
of 73mmHg
associated with new radiographic infiltrates (Figure 1(a)(C)),
requiring admission to the Intensive Care Unit (ICU),
emergent orotracheal intubation, and initiation of invasive
mechanical ventilation. A severe obstructive pattern was
observed with impossibility of ventilation and chest radiog-
raphy revealed complete bilateral infiltrates (Figure 1(a)(D)).
The patient persisted with severe respiratory insufficiency.
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Figure 1: Radiological and bronchoscopic findings. (a) Radiological findings. (A) Chest radiography (CRx) at hospital admission (day 1). (B)
Computed tomography revealing small lingula consolidation (day 2). (C) CRx at ICU admission with new bilateral infiltrates (day 3). (D) CRx
after 24 h of ICU admittance showing bilateral atelectasis (day 4). (b) Bronchoscopic findings. (A) Necrotic detritus and pseudomembrane
in the right upper lobe. (B) Right upper lobe and right carina with an extensive deposit of necrotic material. Bronchoscopic biopsy was
performed and revealed the presence of fungus with hyphae suggestive of Aspergillus. (C) Involvement of intermediate bronchus. (D) The
orifice of bronchus in the culmen was not visible because of a large quantity of necrotic material. Bronchial wash fluid revealed the presence
of Aspergillus. (E) Necrotic detritus and pseudomembrane in the left upper lobe. (F) Involvement of culmen, left carina, and lingula.
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Figure 2: Pathological findings. (a) Lung.The image shows left and right lungs with bilateral necrotizing pneumonia with vascular invasion.
Left lung weight: 875 gr. Right lung weight: 1040 gr. (b) Trachea.The trachea andmain bronchi affected by invasive aspergillosis. (c) Heart.The
white nodule in the left ventriclewas reported as aspergilloma. (d) Brain. Several hemorrhagic andnecrotic areas caused by septicmicroemboli
of Aspergillus.
Prone positioning was not effective and an ECMO was
inserted within the first 24 hr. of ICU admission. Fiber-optic
bronchoscopy showed a large quantity of necrotic material at
the distal bronchial tree, with impossibility of progress with
the bronchoscope to subsegmental bronchi (Figure 1(b)).The
serology was positive for galactomannan whereas histologic
studies and culture of three different samples of the mucosa
revealed Aspergillus fumigatus and Aspergillus flavus. We
started intravenous voriconazole, caspofungin, andnebulized
liposomal amphotericin.Oneweek later the patient presented
hemodynamic instability, worsening renal function and pro-
gressivemultiorgan failure, and death. A forensic autopsywas
performed showing invasive pulmonary aspergillosis (IPA)
with disseminated infection involving lungs (bilateral necro-
tizing pneumonia), brain (necrotic and hemorrhagic spots
suggesting septic emboli), heart, and kidneys (see Figure 2).
2. Discussion
The IPA is a rare pathology and the most devastating form of
Aspergillus infection, characterized by invasion and necrosis
of lung parenchyma [1]. There are several recognized risk
factors to develop IPA, most of them related to different types
of immunodeficiencies [2]. Classical risk factors associated
with IPA include systemic or local radiotherapy, chemother-
apy, airway constriction, prior inhaled (more than 2 weeks)
or systemic (more than 3 weeks) corticosteroid use, hypopro-
teinaemia, prior antibiotic therapy (more than 2 weeks),
neutropenia (less than 500 neutrophils/mm3 for more than
10 days), and chronic granulomatous diseases [3]. The risk of
IPA correlates with the duration and degree of neutropenia
and is higher following allogenic rather than autologous
hematopoietic stem cell transplantation. Also, patients with
severe graft versus host disease after hematopoietic stem cell
transplantation, after solid organ transplantation, CMV lung
infection, and CD4 count less than 100 cells/mm3 have a
higher incidence of IPA [2]. In all of these conditions, IPA
has a significant mortality ranging from 50% in neutropenic
patients to 90% in hematopoietic stem cell transplantation
patients [3, 4].
Patients admitted to ICU also showed an increased
frequency of IPA (ranging from 0.33% to 6.9%) [3, 5]. Risk
factors identified in ICU patients include chronic obstructive
pulmonary disease, cirrhosis, solid organ transplantation,
and severe sepsis [6].
Other factors associated with IPA in ICU include severe
burns, short steroid treatment (less than 7 days), prolonged
ICU stay (more than 21 days), malnutrition, and postcardiac
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surgery status [7].Here, we report a previously healthy patient
who developed IPA without any evidence of risk factors for
this condition. The presence of IPA in nonimmunocom-
promised patients is growing [8–10]. Most of the reports
are single cases initially treated with empiric antibiotics
because of mild symptoms, some receiving antituberculosis
treatment due to atypical presentation and high frequency of
tuberculosis in the region, until the diagnosis of IPA [11, 12].
More than half of immunocompetent patients with invasive
aspergillosis have underlying diseases (tuberculosis infection,
diabetes mellitus, bronchiectasis, pulmonary sequestration,
solid cancer, or chronic liver disease) [13]. However, to our
knowledge dehydration and acute kidney injury, the only
factors identified in this case, are not associated with IPA.
In some cases IPA is related to previous colonization of the
bronchial tree leading to epithelial damage and invasion [2]
or to heavy inoculum ofAspergillus [10].There is no evidence
that any of these two circumstances affected our patient.
The diagnosis of IPA remains challenging and a high
index of suspicion is necessary. A retrospective cohort study
of nonneutropenic patients with (80%) or without (20%)
underlying conditions and diagnosed with IPA demonstrated
that clinical presentation (cough, dyspnea, fever, weight
loss, hemoptysis, chest tightness, or chest pain) was similar
[14]. Other studies suggest that hemoptysis is an important
symptom present in around 60% of patients with IPA, but
that in general, the clinical findings in patients without risk
factors are nonspecific and do not aid in the diagnosis [13].
The typical radiological signs (presence of air crescent sign
and the halo sign in CRx or CT scan) were not observed in
any condition, whereas bronchoscopic findings and cultures
were comparable [14]. In this case, the patient had wheezing,
dyspnea, and severe respiratory insufficiency along with new
radiological infiltrates nonsuggestive of IPA initially oriented
as acute respiratory distress syndrome and aspiration pneu-
monia. The association of nonspecific clinical findings and
the atypical radiological manifestations makes the diagnosis
of IPA difficult and leads to a high misdiagnosis rate [13].
The histopathological examination of lung tissue by
thoracoscopic or open-lung biopsy is the gold standard to
diagnose IPA. Here, because of impossibility of progressing
distally, we obtained a biopsy of the necrotic material in
proximal bronchi, revealing the presence of two Aspergillus
species. Mixed infection of different Aspergillus species is
rarely reported in the literature [15] and associated with
severe immunodepression and treatment failure, making our
case even more exceptional.
Voriconazole 6mg/kg IV b.i.d. for 1 day, followed by
4mg/kg IV b.i.d., is the primary therapy for IPA [16]. We
added caspofungin 70mg in the first day and 50mg the day
thereafter due to the severity of the disease and the presence of
two different Aspergillus species. Finally, we added nebulized
liposomal amphotericin B to the treatment as an adjuvant
therapy according to previous reports [17].
The risk factors associatedwith disseminated aspergillosis
are the same for IPA. However, there are few cases reported
in the literature in immunocompetent patients [9, 11, 12, 18].
In our case the patient had no relevant past medical history,
the analysis did not reveal immunocompromise, tumoral
markers were negative, and the pathological findings did
not show any underlying disease besides the disseminated
aspergillosis. So the presence of IPA with disseminated
infection and the presence of two differentAspergillus species
in the same patient were unexpected. Early diagnosis and cor-
rect aggressive treatment are associated with better outcome
in patients with IPA [11]. However, although we initiated
early appropriate aggressive treatment, the patient developed
multiorgan failure and death revealing the severity of IPA in
nonimmunocompromised patients.
Additional Points
Learning objectives are as follows:
(i) To have invasive pulmonary aspergillosis into the
differential diagnostics in acute respiratory failure
in emergency room or intensive care when more
common etiologies are excluded and the patient has
no adequate clinical response to antibiotic therapy.
(ii) To understand that in rare cases severe invasive
pulmonary aspergillosis with disseminated infection
can affect immunocompetent patients.
CanMEDS Competency: Medical Expert
Pretest questions are as follows:
(1) Which are the frequency and mortality rates of
invasive aspergillosis infection in immunocompetent
patients admitted to an Intensive Care Unit?
(2) How to diagnose invasive pulmonary aspergillosis in
nonimmunocompromised patients?
Posttest questions are as follows:
(1) Which are the frequency and mortality rates of
invasive aspergillosis infection in immunocompetent
patients admitted to an Intensive Care Unit?
The incidence of invasive aspergillosis in ICU is
around 0.33 but some studies report it as high
as 6.9% in ICU population. The mortality rates
are around 38% in colonized patients and 67%
in putative invasive aspergillosis but can be as
high as 80% (almost similar to the incidence in
hematopoietic stem cell transplantation recipi-
ents).
(2) How to diagnose invasive pulmonary aspergillosis in
nonimmunocompromised patients?
There is no specific clinical presentation of inva-
sive pulmonary aspergillosis in immunocom-
petent patients. Also, the classical radiological
signs in chest X-rays or computer tomography
are absent. A high index of suspicion, bron-
choscopy findings, microbiological sampling,
and pulmonary biopsy are the main stem for
diagnosis of IPA in immunocompetent patients.
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